1. Wirdefeldt K, Adami HO, Cole P, et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011;26 Suppl 1:S1–58.
2. O’Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 2008;23:101–6.
3. Ali K, Morris HR. Parkinson’s disease: chameleons and mimics. Pract Neurol 2015;15:14–25.
4. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044–53.
5. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54:93–101.
6. Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson’s disease. Eur J Neurol 2009;16:450–6.
7. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–9.
8. Rajput AH, Rozdilsky B, Ang L. Occurrence of resting tremor in Parkinson’s disease. Neurology 1991;41:1298–9.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.
10. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150–7.
11. Raethjen J, Austermann K, Witt K, et al. Provocation of Parkinsonian tremor. Mov Disord 2008;23:1019–23.
12. Roze E, Coêlho-Braga MC, Gayraud D, et al. Head tremor in Parkinson’s disease. Mov Disord 2006;21:1245–8.
13. Hallett M. Parkinson revisited: pathophysiology of motor signs. Adv Neurol 2003;91:19–28.
14. Broussolle E, Krack P, Thobois S, et al. Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord 2007;22:909–14.
15. Riley D, Lang AE, Blair RD, et al. Frozen shoulder and other shoulder disturbances in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989;52:63–6.
16. Rottach KG, Riley DE, DiScenna AO, et al. Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. Ann Neurol 1996;39:368–77.
17. Cooper JA, Sagar HJ, Tidswell P, Jordan N. Slowed central processing in simple and go/no-go reaction time tasks in Parkinson’s disease. Brain 1994;117(Pt 3):517–29.
18. Almeida QJ, Lebold CA. Freezing of gait in Parkinson’s disease: a perceptual cause for a motor impairment? J Neurol Neurosurg Psychiatry 2010;81:513–8.
19. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurology 2014;71:499–504.
20. Burn DJ, Rowan EN, Allan LM, et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:585–9.
21. Burn DJ, Landau S, Hindle JV, et al; PROMS-PD Study Group. Parkinson’s disease motor subtypes and mood. Mov Disord 2012;27:379–86.
22. Katz M, Luciano MS, Carlson K, et al; CSP 468 study group. Differential effects of deep brain stimulation target on motor subtypes in Parkinson’s disease. Ann Neurol 2015;77:710–9.
23. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010;67:798–801.
24. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 2014;29:454–62.
25. Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord 2015;30:80–9.
26. Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005;20 Suppl 12:S11–20.
27. Karantzoulis S, Galvin JE. Update on dementia with Lewy bodies. Curr Transl Geriatr Exp Gerontol Rep 2013;2:196–204.
28. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94–8.
29. Kim HJ, Jeon BS, Jellinger KA. Diagnosis and differential diagnosis of MSA: boundary issues. J Neurol 2015 Feb 7. [Epub ahead of print]
30. Lee EA, Cho HI, Kim SS, Lee WY. Comparison of magnetic resonance imaging in subtypes of multiple system atrophy. Parkinsonism Relat Disord 2004;10:363–8.
31. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988;38:1031–4.
32. Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986;36:1005–8.
33. Gröschel K, Kastrup A, Litvan I, Schulz JB. Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology 2006;66:949–50.
34. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994117(Pt 5):1183–96.
35. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999;53:1969–74.
36. Tokumaru AM, O’uchi T, Kuru Y, et al. Corticobasal degeneration: MR with histopathologic comparison. AJNR Am J Neuroradiol 1996;17:1849–52.
37. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496–503.
38. Alexander SK, Rittman T, Xuereb JH, et al. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 2014;85:925–9.
39. Sibon I, Fenelon G, Quinn NP, Tison F. Vascular parkinsonism. J Neurol 2004;251:513–24.
40. Thanvi B, Lo N, Robinson T. Vascular parkinsonism--an important cause of parkinsonism in older people. Age Ageing 2005;34:114–9.
41. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson’s disease: a systematic review. Mov Disord 2010;25:149–56.
42. Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol 2013; 12:597–608.
43. Josephs KA. Frontotemporal lobar degeneration. Neurol Clin 2007;25:683–96, vi.
44. Lopez-Sendon J, Mena MA, de Yebenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2013;12:487–96.
45. Mena MA, de Yebenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2006;5:759–71.
46. Brajkovic LD, Svetel MV, Kostic VS, et al. Dopamine transporter imaging (123)I-FP-CIT (DaTSCAN) SPET in differential diagnosis of dopa-responsive dystonia and young-onset Parkinson’s disease. Hell J Nucl Med 2012;15:134–8.
47. Krusz JC, Koller WC, Ziegler DK. Historical review: abnormal movements associated with epidemic encephalitis lethargica. Mov Disord 1987;2:137–41.
48. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979–80.
49. Jankovic J. Searching for a relationship between manganese and welding and Parkinson’s disease. Neurology 2005;64:2021–8.
50. Jankovic J, Kirkpatrick JB, Blomquist KA, et al. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology 1985;35:227–34.
51. Cloud L, Jankovic J. Systemic disease and movement disorders. In: Burn DJ, editor. Oxford textbook of clinical neurology on movement disorders. Oxford University Press; 2013.
52. Bugalho P, Guimaraes J. Gait disturbance in normal pressure hydrocephalus: a clinical study. Parkinsonism Relat Disord 2007;13:434–7.
53. Jankovic J, Newmark M, Peter P. Parkinsonism and acquired hydrocephalus. Mov Disord 1986;1:59–64.
54. Bergsneider M, Black PM, Klinge P, et al. Surgical management of idiopathic normal-pressure hydrocephalus. Neurosurgery 2005;57(3 Suppl): S29-39; discussion ii-v.
55. Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential tremor. Neurology 2000; 54(11 Suppl 4): S7.
56. Jankovic J. Essential tremor and Parkinson’s disease. Ann Neurol 1989;25:211–2.
57. Catafau AM, Tolosa E; DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175–82.
58. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013;84:1288–95.
59. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010;81:5–12.
60. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.
